171 related articles for article (PubMed ID: 20002156)
41. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
42. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
Martin-Algarra S; Bishop MR; Tarantolo S; Cowles MK; Reed E; Anderson JR; Vose JM; Bierman P; Armitage JO; Kessinger A
Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938
[TBL] [Abstract][Full Text] [Related]
43. Risk factors for acute graft-versus-host disease in 291 consecutive HLA-identical bone marrow transplant recipients.
Hägglund H; Boström L; Remberger M; Ljungman P; Nilsson B; Ringdén O
Bone Marrow Transplant; 1995 Dec; 16(6):747-53. PubMed ID: 8750264
[TBL] [Abstract][Full Text] [Related]
44. Prophylaxis of graft-versus-host disease with cyclosporine-prednisone is associated with increased risk of chronic graft-versus-host disease.
Kumar S; Chen MG; Gastineau DA; Gertz MA; Inwards DJ; Lacy MQ; Tefferi A; Harmsen WS; Litzow MR
Bone Marrow Transplant; 2001 Jun; 27(11):1133-40. PubMed ID: 11551023
[TBL] [Abstract][Full Text] [Related]
45. Microangiopathy following allogeneic marrow transplantation. Association with cyclosporine and methylprednisolone for graft-versus-host disease prophylaxis.
Kalhs P; Brugger S; Schwarzinger I; Greinix HT; Keil F; Kyrle PA; Knöbl P; Schneider B; Höcker P; Linkesch W
Transplantation; 1995 Nov; 60(9):949-57. PubMed ID: 7491699
[TBL] [Abstract][Full Text] [Related]
46. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
[TBL] [Abstract][Full Text] [Related]
47. Intensification of GVHD prophylaxis with low-dose ATG-F before allogeneic PBSC transplantation from HLA-identical siblings in adult patients with hematological malignancies: results from a retrospective analysis.
Bonifazi F; Bandini G; Arpinati M; Tolomelli G; Stanzani M; Motta MR; Rizzi S; Giudice V; Dan E; Massari E; Tazzari P; Bontadini A; Pagliaro P; Baccarani M
Bone Marrow Transplant; 2012 Aug; 47(8):1105-11. PubMed ID: 22101198
[TBL] [Abstract][Full Text] [Related]
48. Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor allogeneic hematopoietic cell transplantation.
Hamilton BK; Rybicki L; Dean R; Majhail NS; Haddad H; Abounader D; Hanna R; Sobecks R; Duong H; Hill BT; Copelan E; Bolwell B; Kalaycio M
Am J Hematol; 2015 Feb; 90(2):144-8. PubMed ID: 25353395
[TBL] [Abstract][Full Text] [Related]
49. Prospective trial of mycophenolate mofetil-cyclosporine A prophylaxis for acute GVHD after G-CSF stimulated allogeneic bone marrow transplantation with HLA-identical sibling donors in patients with severe aplastic anemia and hematological malignancies.
Ostronoff F; Ostronoff M; Souto-Maior AP; Domingues M; Sucupira A; Manso DA; de Lima AK; Monteiro PG; Florêncio R; Calixto R
Clin Transplant; 2009; 23(1):33-8. PubMed ID: 18727660
[TBL] [Abstract][Full Text] [Related]
50. De novo chronic graft-versus-host disease in marrow graft recipients given methotrexate and cyclosporine: risk factors and survival.
Wagner JL; Seidel K; Boeckh M; Storb R
Biol Blood Marrow Transplant; 2000; 6(6):633-9. PubMed ID: 11128814
[TBL] [Abstract][Full Text] [Related]
51. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation.
Ratanatharathorn V; Nash RA; Przepiorka D; Devine SM; Klein JL; Weisdorf D; Fay JW; Nademanee A; Antin JH; Christiansen NP; van der Jagt R; Herzig RH; Litzow MR; Wolff SN; Longo WL; Petersen FB; Karanes C; Avalos B; Storb R; Buell DN; Maher RM; Fitzsimmons WE; Wingard JR
Blood; 1998 Oct; 92(7):2303-14. PubMed ID: 9746768
[TBL] [Abstract][Full Text] [Related]
52. Effect of graft-versus-host disease on the outcome of bone marrow transplantation from an HLA-identical sibling donor using GVHD prophylaxis with cyclosporin A and methotrexate.
Kanda Y; Izutsu K; Hirai H; Sakamaki H; Iseki T; Kodera Y; Okamoto S; Mitsui H; Iwato K; Hirabayashi N; Furukawa T; Maruta A; Kasai M; Atsuta Y; Hamajima N; Hiraoka A; Kawa K
Leukemia; 2004 May; 18(5):1013-9. PubMed ID: 15029208
[TBL] [Abstract][Full Text] [Related]
53. Low-dose cyclosporin A with short-term methotrexate for graft-versus-host disease prophylaxis in allogeneic bone marrow transplantation from human leukocyte antigen-identical siblings: a prospective phase II study in Japanese patients.
Kohno A; Morishita Y; Iida H; Sakamaki H; Yokozawa T; Kitaori K; Ozeki K; Matsuo K; Sao H
Int J Hematol; 2006 Jul; 84(1):83-9. PubMed ID: 16867909
[TBL] [Abstract][Full Text] [Related]
54. Posttransplant cyclophosphamide vs cyclosporin A and methotrexate as GVHD prophylaxis in matched sibling transplantation.
Kwon M; Bailén R; Pascual-Cascón MJ; Gallardo-Morillo AI; García Sola A; Balsalobre P; Solán L; Dorado N; Muñoz C; Serrano D; Martínez-Laperche C; Buño I; Anguita J; Díez-Martin JL
Blood Adv; 2019 Nov; 3(21):3351-3359. PubMed ID: 31698447
[TBL] [Abstract][Full Text] [Related]
55. Low-dose methotrexate may preserve a stronger antileukemic effect than that of cyclosporine after modified donor lymphocyte infusion in unmanipulated haploidentical HSCT.
Yan CH; Xu LP; Liu DH; Chen H; Wang Y; Wang JZ; Wang FR; Han W; Liu KY; Huang XJ
Clin Transplant; 2015 Jul; 29(7):594-605. PubMed ID: 25969866
[TBL] [Abstract][Full Text] [Related]
56. Favorable outcomes of tacrolimus compared with cyclosporine A for GVHD prophylaxis in HSCT for standard-risk hematological diseases.
Nasu R; Nannya Y; Shinohara A; Ichikawa M; Kurokawa M
Ann Hematol; 2014 Jul; 93(7):1215-23. PubMed ID: 24590535
[TBL] [Abstract][Full Text] [Related]
57. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-vs.-host disease: effect on chronic graft-vs.-host disease and long-term survival.
Ross M; Schmidt GM; Niland JC; Amylon MD; Dagis AC; Long GD; Nademanee AP; Negrin RS; O'Donnell MR; Parker PM; Smith EP; Snyder DS; Stein AS; Wong RM; Forman SJ; Blume KG; Chao NJ
Biol Blood Marrow Transplant; 1999; 5(5):285-91. PubMed ID: 10534058
[TBL] [Abstract][Full Text] [Related]
58. Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial.
Locatelli F; Bruno B; Zecca M; Van-Lint MT; McCann S; Arcese W; Dallorso S; Di Bartolomeo P; Fagioli F; Locasciulli A; Lawler M; Bacigalupo A
Blood; 2000 Sep; 96(5):1690-7. PubMed ID: 10961865
[TBL] [Abstract][Full Text] [Related]
59. Effect of graft-versus-host disease prophylaxis on relapse in patients transplanted for acute myeloid leukemia.
Weaver CH; Clift RA; Deeg HJ; Storb R; Appelbaum FR; Bensinger W; Doney K; Hansen JA; Martin PO; Sanders J
Bone Marrow Transplant; 1994 Dec; 14(6):885-93. PubMed ID: 7711667
[TBL] [Abstract][Full Text] [Related]
60. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate.
Nash RA; Pepe MS; Storb R; Longton G; Pettinger M; Anasetti C; Appelbaum FR; Bowden RA; Deeg HJ; Doney K
Blood; 1992 Oct; 80(7):1838-45. PubMed ID: 1391947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
